Showing results (111-120 of 255) with videos related to
Sort By:
Pageof 26
Journal of the National Cancer Institute|January 2, 2017
T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for TreatmentCarla Casulo, Owen O'Connor, Andrei Shustov, et al.British Journal of Haematology|January 6, 2016
Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern eraLoretta J Nastoupil, Rajni Sinha, Michelle Byrtek, et al.British Journal of Haematology|April 9, 2015
Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United StatesChadi Nabhan, Michelle Byrtek, Ashish Rai, et al.Blood|August 30, 2002
Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factorsAndrea K Ng, M V Patricia Bernardo, Edie Weller, et al.Blood|February 7, 2009
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximabShannon P Hilchey, Ollivier Hyrien, Tim R Mosmann, et al.Leukemia & Lymphoma|September 30, 2014
Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United StatesLoretta J Nastoupil, Rajni Sinha, Michelle Byrtek, et al.Archives of Pathology & Laboratory Medicine|December 7, 2023
T-Cell-Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic FeaturesSiba El Hussein, Hong Fang, Fatima Zahra Jelloul, et al.British Journal of Haematology|June 13, 2002
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphomaJonathan W Friedberg, Donna Neuberg, John G Gribben, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomasJonathan W Friedberg, Daruka Mahadevan, Erin Cebula, et al.Blood|October 18, 2017
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HLJonathan W Friedberg, Andres Forero-Torres, Rodolfo E Bordoni, et al.Pageof 26